First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 5.55 USD -1.07% Market Closed
Updated: Apr 19, 2024

Editas Medicine Inc
Capital Expenditures

Last Value
3-Years CAGR
5-Years CAGR
Quarterly
Annual
TTM
|

Editas Medicine Inc
Capital Expenditures Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Editas Medicine Inc
NASDAQ:EDIT
Capital Expenditures
$-4m
CAGR 3-Years
17%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Capital Expenditures
$-777m
CAGR 3-Years
1%
CAGR 5-Years
-4%
CAGR 10-Years
-5%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
$-585m
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
-12%
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
$-1.1B
CAGR 3-Years
-22%
CAGR 5-Years
-9%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
$-258.4m
CAGR 3-Years
0%
CAGR 5-Years
-22%
CAGR 10-Years
-18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
$-926.4m
CAGR 3-Years
-15%
CAGR 5-Years
-19%
CAGR 10-Years
-19%

See Also

What is Editas Medicine Inc's Capital Expenditures?
Capital Expenditures
-4m USD

Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Capital Expenditures amounts to -4m USD.

What is Editas Medicine Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
3%

Over the last year, the Capital Expenditures growth was 2%. The average annual Capital Expenditures growth rates for Editas Medicine Inc have been 17% over the past three years , 3% over the past five years .